GlassScriptPhysician profile
Allyson D Johnson
NPI 1376933663
$826.77
in general payments reported to CMS, 2019-2025
19 companies · $420 in 2025
The $420 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $20.58 · 2024: $387 · 2025: $420.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $827.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $826.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $182.52 | 2024-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $162.10 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $133.49 | 2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $40.15 | 2025 | |
| Ardelyx, INC. | $39.12 | 2025 | Ibsrela |
| Phathom Pharmaceuticals, INC. | $32.03 | 2024-2025 | Voquezna |
| Takeda Pharmaceuticals U.S.A., INC. | $29.18 | 2025 | Trintellix |
| Mindray Ds USA, INC. | $25.08 | 2024 | A7 Anesthesia System |
| Glaxosmithkline, LLC. | $20.58 | 2023 | Pediarix, Bexsero |
| Axsome Therapeutics, INC. | $19.11 | 2025 | Symbravo |
| Abbvie INC. | $18.17 | 2024 | |
| Sumitomo Pharma America, INC. | $18.01 | 2025 | Gemtesa |
| Boston Scientific Corporation | $17.00 | 2025 | Watchman Access System |
| Dexcom, INC. | $16.90 | 2024 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $16.72 | 2025 | Inspire |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Philips North America LLC | $15.14 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Exact Sciences Corporation | $14.20 | 2024 | Cologuard Collection Kit |
| Shield Therapeutics INC | $14.04 | 2025 | |
| Idorsia Pharmaceuticals US INC | $13.23 | 2024 | Quviviq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.